Scarica l'app Stockscreener
7.53
1.31%
-0.10
Dopo l'orario di chiusura:
7.33
-0.20
-2.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AVXL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.63
Aprire:
$7.5
Volume 24 ore:
841.74K
Relative Volume:
0.85
Capitalizzazione di mercato:
$642.84M
Reddito:
-
Utile/perdita netta:
$-43.16M
Rapporto P/E:
-13.69
EPS:
-0.55
Flusso di cassa netto:
$-29.31M
1 W Prestazione:
+0.00%
1M Prestazione:
-21.81%
6M Prestazione:
-20.40%
1 anno Prestazione:
+81.88%
Intervallo 1D:
$7.31
$7.62
Intervallo di 1 settimana:
$7.26
$7.81
Portata 52W:
$3.51
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Nome
Anavex Life Sciences Corporation
Settore
Industria
Telefono
844-689-3939
Indirizzo
630 5TH AVENUE, NEW YORK
Confronta AVXL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
7.53 | 642.85M | 0 | -43.16M | -29.31M | -0.55 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-09-23 | Iniziato | BTIG Research | Buy |
| 2020-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-28 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-02-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-18 | Iniziato | Janney | Buy |
| 2018-05-16 | Ripresa | Maxim Group | Buy |
| 2018-03-08 | Iniziato | ROTH Capital | Buy |
| 2018-02-13 | Reiterato | Maxim Group | Buy |
| 2017-09-29 | Ripresa | Noble Financial | Buy |
| 2017-02-07 | Iniziato | Noble Financial | Buy |
| 2016-03-29 | Iniziato | FBR Capital | Outperform |
Mostra tutto
Anavex Life Sciences Corporation Borsa (AVXL) Ultime notizie
Deutsche Bank AG Has $693,000 Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
D. E. Shaw & Co. Inc. Purchases Shares of 105,130 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Northern Trust Corp Raises Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
The Manufacturers Life Insurance Company Has $298,000 Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
HC Wainwright Issues Positive Forecast for AVXL Earnings - Defense World
Anavex Life Sciences Corp.'s (NASDAQ:AVXL) largest shareholders are individual investors with 60% ownership, institutions own 37% - Yahoo Finance
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Tower Research Capital LLC TRC Buys 1,708 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlight - GuruFocus
Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2025 Earnings Call Transcript - Insider Monkey
Anavex Life Sciences to Participate at Upcoming Healthcare Confe - GuruFocus
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences | AVXL Stock News - GuruFocus
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences - The Manila Times
Anavex Brings Alzheimer's and Parkinson's Drug Updates to Prestigious Wainwright Healthcare Conferences - Stock Titan
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot - CT Insider
Anavex Life Sciences Reports Q2 2025 Financial Results - TipRanks
Raymond James Financial Inc. Makes New $167,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Earnings call transcript: Anavex Life Sciences Q2 2025 reports net loss, stock rises - Investing.com Nigeria
Anavex Life Sciences (AVXL) Q2 Earnings Exceed Expectations - GuruFocus
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financia - GuruFocus
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update - The Manila Times
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update | AVXL Stock News - GuruFocus
Anavex Life Sciences Corp. Reports Q2 Fiscal 2025 Financial Results and Updates on Clinical Developments - Nasdaq
Anavex Life Sciences Corp. Q2 Loss Beats Estimates - Nasdaq
Anavex Life Sciences Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Closing Bell Recap: Anavex Life Sciences Corporation (AVXL) Ends at 8.91, Reflecting a -4.81 Downturn - DWinneX
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Fina - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 | AVXL Stock News - GuruFocus
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - The Manila Times
Anavex Life Sciences Corp. to Announce Second Fiscal Quarter Financial Results on May 13, 2025 - Nasdaq
Anavex Life Sciences Earnings Preview: Key Updates Coming on Alzheimer's and Rare Disease Programs - Stock Titan
Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World
Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com
Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference - The Manila Times
Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan
Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. to Present at The Citizens Life Sciences Conference in New York, May 2025 - Nasdaq
Press Release Distribution & PR Platform - ACCESS Newswire
Anavex Life Sciences Corporation Azioni (AVXL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):